# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Paul Choi downgrades Cytokinetics (NASDAQ:CYTK) from Buy to Neutral and lowers the price target from $...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(1.02...
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $77 t...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...